New head-to-head data from IMMerge phase IIIb study of risankizumab versus secukinumab in patients with psoriasis presented at conference

Study in 327 adult patients with moderate to severe plaque psoriasis reported that risankizumab met both PASI 90 primary endpoints of non-inferiority to secukinumab at week 16 (74 vs. 66%, respectively) and superiority to secukinumab at week 52 (87% vs. 57%).


Biospace Inc.